Ce poste de technicien d'étude clinique est à pourvoir au sein de l’unité de recherche INSERM U970 dans l’équipe 11 : Approches multidimensionnelles en transplantation d’organes dirigée par le Pr Alexandre Loupy.
Ce poste s’intègre au sein d’un projet se focalisant sur la transplantation pulmonaire. Actuellement, la prédiction du succès ou de l’échec d’une greffe pulmonaire reste difficile car les mécanismes immunologiques autour d’un greffon sont mal connus.
Notre équipe s’intéresse aux approches personnalisées pour la prédiction de risque post-transplantation (notamment les risques de survenue de rejet) par l’intégration d’informations multidimensionnelles. Cela regroupe des données provenant de la clinique, de l’histologie classique, de la biologie et éventuellement des données provenant de technologies innovantes en immunologie, biologie moléculaire, génétique et biomarqueurs.

Ce poste d'assistant de recherche clinique est à pourvoir au sein de l’unité de recherche INSERM U970 dans l’équipe 11 : Approches multidimensionnelles en transplantation d’organes dirigée par le Pr Alexandre Loupy.
Notre équipe s’intéresse aux approches personnalisées en médecine de la transplantation par l’intégration d’informations multidimensionnelles provenant de l’histologie classique, de la biologie et de la science clinique ainsi que des informations nouvelles provenant de technologies innovantes en immunologie, biologie moléculaire, génétique et biomarqueurs.
Ce poste s’intègre dans le cadre d’un nouveau projet se focalisant sur la transplantation hépatique ayant pour objectifs : de précision diagnostique et la stratification du rejet en transplantation hépatique.

The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. 

His/her duties will include creating various machine learning-based tools or processes within the team, such as recommendation engines or automated lead scoring systems. The resource within this role should also be able to perform statistical analysis. You are detail-oriented, meticulous, and an analytical team player. You ask the right questions, effectively communicate across teams, and want an opportunity to help shape what data can offer to our knowledge of organ transplantation.

Accurate risk stratification of early heart transplant failure is required to avoid futile transplants and rationalize donor selection. We aimed to evaluate the statistical performance of existing risk scores on a contemporary cohort of heart transplant recipients.

After an exhaustive search, we identified 16 relevant risk scores. From the UNOS database, we selected all first noncombined adult heart transplants performed between 2014 and 2017 for validation. The primary endpoint was death or retransplant during the first year posttransplant.

​For all scores, we analyzed their association with outcomes, sensitivity, specificity, likelihood ratios, and discrimination (concordance index and overlap of individual scores). The cohort included 9396 patients. All scores were significantly associated with the primary outcome (P < .001 for all scores). Their likelihood ratios, both negative and positive, were poor. The discriminative performance of all scores was limited, with concordance index ranging from 0.544 to 0.646 (median 0.594) and an important overlap of individual scores between patients with or without the primary endpoint. Subgroup analyses revealed important variation in discrimination according to donor age, recipient age, and the type of assist device used at transplant.

Our findings raise concerns about the use of currently available scores in the clinical field.

One of the most common reasons for long-term graft failure and patient death is an accelerated form of coronary artery disease called cardiac allograft vasculopathy. It is a frequent complication that affects up to half of patients within 10 years following heart transplantation. Yet, until now, little has been known about the different evolutive profiles of cardiac allograft vasculopathy and their risk factors.